BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CompleGen And DuPont (DD) Crop Protection Sign Agreement To Allow CompleGen Access To A Large Compound Chemical Library


10/19/2005 5:09:53 PM

SEATTLE and WILMINGTON, Del., Sept. 24 /PRNewswire/ -- CompleGen announced today the signing of an agreement with DuPont Crop Protection allowing CompleGen access to a large chemical library in exchange for a series of CompleGen's XenoGene(TM) assays. The chemical library consists of compounds highly selected for drug-like properties. XenoGene(TM) assays are genetically modified yeast requiring a foreign (target) gene to grow, allowing the high throughput screening of compounds to identify those that act specifically on the protein encoded by the foreign gene.

The agreement gives DuPont Crop Protection rights to certain assays and all compounds discovered with the assays in the Agricultural field of use. In return, CompleGen has all rights in the Pharmaceutical field to discoveries that come from this library. Dr. Joe Hedgpeth, CompleGen's CEO and co-founder, states: "We are delighted to extend our relationship with DuPont Crop Protection in this collaboration. Our previous work has been productive for both companies and has helped CompleGen validate its technology. The current agreement is evidence of the creativity of both companies in structuring a mutually beneficial relationship. Access to this compound library provides us with a large library unavailable elsewhere with which to screen our XenoGene(TM) targets. Further, this agreement will enhance the ability of DuPont Crop Protection to apply targeted high throughput screening, normally available only to pharmaceutical discovery, to their discovery programs. CompleGen currently has a backlog of more than 150 XenoGenes(TM) of pharmaceutical interest ready for screening. We believe this high-quality chemical library will allow CompleGen to leverage its novel biology into novel chemistry and allow the company to discover and patent novel drugs at an otherwise unachievable rate, industrialize the pre-clinical drug development process and dramatically reduce the time it takes to bring a drug to market."

"DuPont Crop Protection is enthusiastic about this important milestone in our relationship with CompleGen", said Pat Confalone, Director, Research & Development. "Coupling of our unique compound library with the proven utility of the XenoGene(TM) system may lead to the discovery of key leads which will provide the basis for further innovation in both the pharmaceutical and crop protection industries. This swap of compound libraries for target-based assays is a very thoughtful exchange which affords mutual benefits to both R&D organizations."

About CompleGen

CompleGen is a development stage biotechnology company located in Seattle, WA. The company uses its proprietary technology to rapidly generate validated drug leads and take them through pre-clinical development (initially targeting large oncology and infectious disease markets). CompleGen has an issued U.S. patent on a novel technology to construct and utilize genetically modified yeast strains as highly effective screening tools to find drug leads from large compound libraries. Significant applications in the development of novel agrochemicals exist as well. The company has prior collaborations with DuPont, Berlex Biosciences (a subsidiary of Schering A.G.) and other large pharmaceutical companies.

About DuPont Crop Protection

DuPont Crop Protection serves production agriculture with products for the grain and specialty crop sectors as well as forestry/vegetation and professional pest management. It includes global herbicide, fungicide, and insecticide products and services. Employees number 3,600 with operations in 60 countries.

CONTACT: Michael Tippie Vice President, Business Development CompleGen, Inc. +1-206-447-9014 mtippie@complegen.com Joel Hedgpeth, Ph.D. President and CEO CompleGen, Inc. +1-206-447-8076 jhedgpeth@complegen.com Gabrielle King Manager, Public Affairs DuPont Crop Protection +1-302-999-5393 gabrielle.king@usa.dupont.com

CompleGen, Inc.

CONTACT: Michael Tippie, Vice President, Business Development,+1-206-447-9014, or mtippie@complegen.com; or Joel Hedgpeth, Ph.D., Presidentand CEO, +1-206-447-8076, or jhedgpeth@complegen.com, both of CompleGen, Inc.;or Gabrielle King, Manager, Public Affairs, of DuPont Crop Protection,+1-302-999-5393, or gabrielle.king@usa.dupont.com



Read at BioSpace.com

DuPont
CompleGen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES